home / stock / tenx / tenx quote
Last: | $3.17 |
---|---|
Change Percent: | 1.22% |
Open: | $2.9633 |
Close: | $3.17 |
High: | $3.2925 |
Low: | $2.9633 |
Volume: | 54,984 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.17 | $2.9633 | $3.17 | $3.2925 | $2.9633 | 54,984 | 07-02-2024 |
$3 | $2.9723 | $3 | $3.0599 | $2.9501 | 16,485 | 07-01-2024 |
$3.0148 | $2.92 | $3.0148 | $3.12 | $2.92 | 4,161 | 06-28-2024 |
$2.98 | $3.09 | $2.98 | $3.1495 | $2.95 | 24,130 | 06-27-2024 |
$3.13 | $3.12 | $3.13 | $3.21 | $3.1 | 30,353 | 06-26-2024 |
$3.21 | $3.0547 | $3.21 | $3.2319 | $3.05 | 23,962 | 06-25-2024 |
$3.02 | $2.77 | $3.02 | $3.06 | $2.77 | 18,880 | 06-24-2024 |
$2.77 | $3.09 | $2.77 | $3.09 | $2.77 | 51,254 | 06-21-2024 |
$3.03 | $3.09 | $3.03 | $3.09 | $3.01 | 22,668 | 06-20-2024 |
$3.09 | $3.1219 | $3.09 | $3.2 | $3.0617 | 17,748 | 06-19-2024 |
$3.09 | $3.1219 | $3.09 | $3.2 | $3.0617 | 17,748 | 06-18-2024 |
$3.1 | $3.16 | $3.1 | $3.185 | $3.03 | 14,558 | 06-17-2024 |
$3.14 | $3.24 | $3.14 | $3.32 | $3.08 | 19,447 | 06-14-2024 |
$3.2 | $3.26 | $3.2 | $3.29 | $3.1593 | 17,228 | 06-13-2024 |
$3.28 | $3.39 | $3.28 | $3.4795 | $3.23 | 56,272 | 06-12-2024 |
$3.42 | $3.39 | $3.42 | $3.43 | $3.3624 | 16,120 | 06-11-2024 |
$3.43 | $3.54 | $3.43 | $3.54 | $3.41 | 13,146 | 06-10-2024 |
$3.45 | $3.535 | $3.45 | $3.54 | $3.45 | 10,535 | 06-07-2024 |
$3.53 | $3.59 | $3.53 | $3.6 | $3.53 | 9,743 | 06-06-2024 |
$3.58 | $3.51 | $3.58 | $3.6 | $3.4843 | 18,622 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...